Harvard Management Company’s Agios Pharmaceuticals AGIO Stock Holding History

Harvard Management Company’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,312	Closed	-$312K	–	122
2015 Q1	$312K	Buy	+3,312	New	+$371K	0.05%	83

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CGT

Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Harvard Management Company's AGIO Position: Q2 2015 in Review

Harvard Management Company sold out of Agios Pharmaceuticals (AGIO) in Q2 2015, closing a stake of 3,312 shares — an estimated $312K sold.

Harvard Management Company first reported a position in AGIO in Q1 2015 and held it in 1 quarter. The position peaked at $312K in Q1 2015. 161 funds tracked by Wall St. Rank hold AGIO as of Q2 2015.

Harvard Management Company reported no remaining Agios Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Harvard Management Company sold 3,312 Agios Pharmaceuticals shares in Q2 2015, an estimated $312K.
Harvard Management Company first reported a position in Agios Pharmaceuticals in Q1 2015 and held it in 1 quarter.
Harvard Management Company's Agios Pharmaceuticals position peaked at $312K in Q1 2015.
161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2015.

Based on Harvard Management Company's 13F filing for Q2 2015, filed 14 Aug 2015.